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Abstract
Lung cancer is the leading cause of cancer-related deaths. The morbidity and mortality of lung cancer have mark-
edly increased in the past decade with at least 75% of patients with lung cancer having evidence of metastases at
the time of diagnosis. It frequently metastasizes to bone resulting in osteolytic lesions with unknown mechanisms.
The aim of this study was to identify factors that mediate lung cancer–induced osteoclast activity in vivo. Using a
human cytokine antibody array, we first determined cytokine levels in a conditioned medium collected from non–
small cell lung cancer A549 and H1299 cells and the non-neoplastic human bronchial epithelial BEAS2B cells. Both
A549 and H1229 cells produced significantly higher amount of several cytokines including monocyte chemotactic
protein 1 (MCP-1) and interleukin 8 (IL-8) compared with BEAS2B cells. These findings were confirmed by ELISA.
From clinical serum specimens, we also observed that MCP-1 and IL-8 levels were increased in lung cancer pa-
tients with bone metastases compared with the patients with localized tumor. Next, we investigated the effects of
MCP-1 on osteoclast formation in vitro using murine bone marrow–derived monocytes. A549 conditioned medium
induced osteoclast formation that was inhibited by neutralizing antibodies against MCP-1. Finally, A549 cells were
stably transfected with MCP-1 short hairpin RNA. The MCP-1 knockdown A549 cells were implanted into the tibia
of severe combined immunodeficient mice for 4 weeks. The MCP-1 knockdown significantly diminished A549 cell
growth. We conclude that MCP-1 promotes lung cancer–induced osteoclast activity and thus bone resorptive le-
sions in vivo.
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Introduction
Lung cancer is the leading cause of cancer-related deaths and is the
second most common malignancy in both men and women [1]. Epi-
demiological study has particularly documented that morbidity and
mortality of lung cancer have markedly increased in the past decade
in China [2], with at least 75% of patients with lung cancer having
evidence of metastases at the time of diagnosis [3]. Lung cancer fre-
quently metastasizes to bone resulting in osteolytic (bone resorptive)
lesions through unknown mechanisms. It has been widely accepted
that the cross talks between tumor cells and the bonemicroenvironment
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may play a key role for tumor cell homing to bone and tumor develop-
ment [4]. The factors responsible for lung cancer–induced osteolysis,
however, have not been well characterized.
Human bronchial epithelial cells produce a number of proinflam-
matory cytokines such as monocyte chemotactic protein 1 (MCP-1),
interleukin 8 (IL-8), and growth-related oncogene α (GROα) that
contributes to the recruitment of inflammatory cells, mucin secretion,
tissue remodeling, and pathogen-killing processes [5]. Monocyte che-
motactic protein 1 has been demonstrated as a member of the CC che-
mokine superfamily that plays a critical role in the recruitment and
activation of monocytes during acute inflammation and angiogenesis
[6–9]. In human lungs, MCP-1 is expressed in a variety of cell types,
namely, macrophages, endothelial, bronchial epithelial, and smooth
muscle cells [10–12]. Recently, it was reported that cancer cells such
as prostate cancer, breast cancer, and multiple myeloma that preferen-
tially home to bone produce MCP-1 and express its receptor CCR2
[9–15]. In patients with breast and ovarian cancers, MCP-1 levels are
increased in their sera, which correlated with the tumor stage [16,17].
We and other researchers have reported that MCP-1, produced by pros-
tate cancer epithelial cells, stroma/osteoblasts, and bone marrow endo-
thelial cells (HBME), is chemotactic for prostate cancer cells [15,18].
We observed thatMCP-1 also increases prostate cancer cell proliferation
and induces osteoclast formation in vitro through its receptor CCR2
[18,19]. Importantly, we reported that CCR2 expression levels correlate
with prostate cancer progression as determined by immunohistochemis-
try [20]. In support of our findings, Loberg et al. [21] recently reported
similar results thatMCP-1, derived from humanHBMEs, induces pros-
tate cancer cell proliferation and migration. More recently, we found
that parathyroid hormone–related protein–induced MCP-1 produc-
tion by HBME cells and osteoblasts promotes osteoclast differentiation
and prostate cancer cell proliferation and invasion in vitro [18]. These
results were mostly from studies in prostate cancer. Whether the roles of
MCP-1 may be extended to lung cancer has become a critical question,
and importantly, there is a lacking of in vivo studies on the roles of
MCP-1 on lung cancer development. Our hypothesis for this study
was that MCP-1 promotes lung cancer–induced bone resorptive lesions
in vivo. Accordingly, we first determined the production of cytokines in
poorly differentiated non–small cell lung cancer cell lines A549 and
H1299 and in the human bronchial epithelial cell line BEAS2B. Fur-
thermore, we investigated the effects of MCP-1 on osteoclast formation
in vitro using murine bone marrow–derived monocytes and the effects




Recombinant human and murine macrophage colony-stimulating
factor, receptor activator of nuclear factor κB ligand (RANKL), IL-8,
MCP-1, IL-8 antibody,MCP-1 antibody, RANKL antibody, and isotype
control antibodies were purchased from R&D Systems (Minneapolis,
MN). All chemical reagents were purchased from Sigma (St. Louis,MO).
Cell Culture
The human non–small cell lung adenocarcinoma A549 and
H1299 cell lines and a nonneoplastic bronchi epithelial BEAS2B
cell line were kindly provided by Dr. Xue Wang (University of
Pittsburgh, Pittsburgh, PA). A529 and BEAS2B cells were cultured
with Dulbecco’s modified Eagle’s medium. H1299 cells were cultured
in RPMI 1640 media (Invitrogen, Carlsbad, CA). The media were
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicil-
lin, and 100 μg/ml streptomycin.
Conditioned Media
BEAS2B,H1299, and A549 cells at 2 × 106 were grown in 100-mm
tissue culture dishes overnight in cell culture media, then washed
twice with PBS and changed the media to 1% FBS in RPMI 1640.
After 48 hours, the conditioned media (CM) were collected. To nor-
malize for differences in cell density because of proliferation during
the culture period, cells from each plate were collected and total
DNA content/plate was determined (spectrophotometric absorbance,
260 nm). Conditioned medium was then normalized for DNA con-
tent between samples by adding RPMI.
Cytokine Antibody Array
Human Cytokine Antibody Array kit was purchased from Ray-
Biotech (Norcross, GA). This array consisted of 174 different anti-
bodies spotted in duplicate. Experiments were performed as previously
described [19]. Briefly, array membranes were incubated for 30 minutes
in blocking buffer and then incubated for 2 hours with 1.5 ml of the
CM collected from BEAS2B, H1299, and A549 or medium of
RPMI 1640 with 1% FBS as control (control media). The membranes
were washed and a diluted cocktail of biotinylated antibodies was
added for 90 minutes. Membranes were then washed again, and the
sandwiched antigens were detected by incubation for 2 hours with a
peroxidase-labeled streptavidin solution diluted to 1:1000. Proteins
were detected finally by enhanced chemiluminescence, and signals
were captured on x-ray films. Array images were acquired at a resolu-
tion of 300 ppi on an MICROTEK scanner and were quantified with
Software ImageQuant TL (Amersham Biosciences Inc, Piscataway,
NJ). The fold changes among samples were analyzed by using RayBio
Antibody Array Analysis Tool provided by the company. For each
spot, the net density gray level was determined by subtracting the
background gray level from the total raw density gray levels. The data
after background subtraction were normalized according to positive
control densities.
Measurement of Cytokines Levels by ELISA
The cytokine levels of the conditioned media collected from
BEAS2B, H1299, and A549 cells and serum from lung cancer pa-
tients and healthy donors were measured by appropriate ELISA kits.
Sera from patients with localized lung cancer (n = 18, median age at
the time of diagnosis was 66.61 years, range 58-88 years), patients
with bone metastases (n = 7, median age at the time of diagnosis
was 61.71 years, range 41-80 years), and healthy age-matched donors
(n = 20, median age at the time of diagnosis was 61.85 years, range
39-79 years) were obtained retrospectively from the Department of
Clinical Chemistry, Tianjin Chest Hospital. The hospital institutional
review board approved the sample collection and experimental proce-
dures. Quantikine human MCP-1, IL-8, growth-related oncogene α
(GROα), epithelial neutrophil-activating peptide-78 (ENA-78), regu-
lated upon activation normal T-cell expressed and secreted (RANTES),
chemokine (C-X-Cmotif ) ligand 16 (CXCL16),matrixmetalloprotein-
ase 9 (MMP-9), tissue inhibitor of metalloproteinase 4 (TIMP-4), IL-4,
and IL-5 ELISA kits were purchased from R&D Systems. ELISAs were
performed according to the instructions from the manufacturer.
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Mouse Bone Marrow–Derived Monocyte Culture
Primary mouse bone marrow cells were obtained by flushing femora
from 4- to 6-week-old C57BL/6 mice. The animal protocol was ap-
proved by the Institutional Animal Care and Use Committee, University
of Pittsburgh. Briefly, the bone marrow cells were incubated in α-
minimum essential medium with 20% FBS overnight at 37°C in
100-mm tissue culture plates to separate nonadherent and adherent cells.
The nonadherent cells were collected and used in cultures as the source
of osteoclast formation assay as described below.
Osteoclast Formation from Mouse Bone
Marrow–Derived Monocyte
Osteoclast formation assays were performed by culturing 1 × 105
nonadherent cells per well in 96-well plates in 0.1 ml of α-minimum
essential medium with 10% FBS for 7 to 10 days. The cells were in-
cubated with recombinant mouse M-CSF (10 ng/ml) and/or RANKL
(50 ng/ml) and 10% CM collected from the BEAS2B, H1299, or
A549 cells in the presence of various doses of neutralizing antibody
against MCP-1, IL-8, and RANKL or isotype control antibodies. Half
of the media was changed at day 4. After 7 days of culture, the cells
were fixed with 2% formaldehyde and stained with K-ASSAY TRAP
staining kit (Kamiya Biomedical, Seattle, WA). The positive staining
cells that contained three or more nuclei were counted as osteoclast-
like cells. Analysis of all osteoclast formation experiments included
data from three independent experiments.
Animal Studies
Male severe combined immunodeficient mice (SCID) mice
(Charles River, Wilmington, MA), 6 weeks of age, were housed under
pathogen-free conditions in accordance with the National Institutes
of Health guidelines. The animal protocol was approved by the Insti-
tutional Animal Care and Use Committee, University of Pittsburgh.
Thirty SCID mice were used in these experiments. Single-cell suspen-
sion of A549 (3 × 105 cells in 20-μl volume of Dulbecco’s modified
Eagle’s medium with 1% FBS) cells that MCP-1 had been knocked
down, at different proportions, by short hairpin RNA (shRNA) tech-
nique or the control cells were injected into the right tibia of SCID
mice (n = 10 per group) as described previously [22]. The tumor cells
were allowed to grow for 4 weeks, at which time the mice were killed.
Evidence of tumor-induced bone changes was evaluated using radio-
graphy (Faxitron X-ray Corp., Wheeling, IL), histology, and bone
histomorphometry. To obtain MCP-1 knockdown cells, the Block-it
RNAi designer (Invitrogen) was used to design shRNA specific to
MCP-1 (Accession No. NM_002982; position 150-197; 5′-TGC
AAT CAA TGC CCC AGT CAC CTG CTG TTA TAA CTT
CACCAATAGGA-3′). TheMCP-1 shRNA controls were generated
by inverting the bases at positions 9 to 13 within theMCP-1 sequences
and were used as scrambled shRNA. Resulting sequences were cloned
into the RNA expression vector pENTR/H1/TO (Invitrogen) and se-
quences were confirmed. Either the MCP-1 shRNA or the scrambled
shRNA was transfected into A549 cells using lipofectamine reagents,
and individual clones were selected using 100 μg/ml Zeocin (Invitro-
gen). Seven clones were evaluated forMCP-1’s functional knockdown.
Specifically, CM was collected from two selected clones. These clones
were used for the in vivo experiment.
Cell Proliferation Assay
Cell proliferationwasmeasured with the use of a CellTiter 96AQeous
NonradioactiveCell ProliferationAssay (Promega,Madison,WI). Briefly,
the cells of selected A549 clones were plated in 96-well plates at a den-
sity of 3000 cells per well, respectively, in 200 μl of RPMI 1640 plus
0.5% FBS. Ten nanograms per milliliter of rhMCP-1 was added into
the cultures. The cells were incubated at 37°C in a humidified 5%
CO2 atmosphere for 24, 48, 72, and 96 hours, then 20 μl of combined
MTS/PMS solution was added. After incubation for 2 hours at 37°C,
the absorbance of each well at 490 nmwas recorded by using an ELISA
plate reader.
Histopathology and Bone Histomorphometry
Histopathology was performed as previously described [23]. Briefly,
bone specimens (tibiae) were fixed in 10% formalin for 24 hours then
decalcified using 10% EDTA for 6 days. The specimens were then
paraffin-embedded, sectioned (4 μM), and stained with hematoxylin
and eosin (H&E) to assess histology or used for TRAP activity staining
(acid phosphatase kit, Model 387-A; Sigma Diagnostics, St. Louis,
MO). For TRAP staining, the specimens were stained with acid phos-
phatase and tartrate solution for 1 hour at 37°C. Four discontinuous
random regions of interest were examined within each tibia. Histo-
morphometric analysis was performed on H&E-stained sections, and
tumor volume was quantified using Bioquant Osteo II (Bioquant Image
Analysis Corp, Nashville, TN) as previously described [23]. The ter-
minology used was that recommended by the Histomorphometry
Nomenclature Committee of the American Society for Bone and Min-
eral Research.
Statistical Analysis
Statistical analysis was performed using Statview software (Abacus
Concepts, Berkley, CA). Analysis of variance was used for initial anal-
yses, followed by Fisher’s protected least significant difference for
post hoc analyses. Student’s t test was used for comparisons between
two groups. Differences with a P < .05 were determined as statisti-
cally significant.
Results
Lung Cancer Cells Produced High Amounts of MCP-1 and IL-8
To identify factors that mediate lung cancer–induced bone lesions,
a human cytokine antibody array was used to screen cytokine produc-
tion by BEAS2B, H1299, and A549 cells using CM collected from
these cells. Lung cancer cell lines H1299 and A549 produced high
amounts of MCP-1, RANTES, ENA-78, GRO, GROα, IL-8, VEGF,
CXCL16, and MMP-9 compared with nonmalignant BEAS2B cells
(Figure 1, A and B). In addition, levels of GROα and ENA-78 were
greater in A549 cells compared with those in H1299 cells. We did not
observe significant differences in production of TIMP-4 (Figure 1, A
and B), IL-4, and IL-5 (data not shown).
Confirmation of Cytokine Array Data by ELISA
To validate the findings in cytokine array experiment, we mea-
sured, by ELISA, the levels of MCP-1, RANTES, ENA-78, GROα,
IL-8, VEGF, CXCL16, MMP-9, TIMP-4, IL-4, and IL-5 in the CM
used for the cytokine array. Consistent with the array observation,
levels of MCP-1, ENA-78, GROα, IL-8, VEGF, CXCL16, and
MMP-9 except for RANTES in H1299 and A549 cells were sig-
nificantly greater than BEAS2B cells, whereas A549 produced the
highest amount of these soluble factors (Figure 2). As expected, we
did not observe significant differences in the production of TIMP-4
(Figure 2), IL-4, and IL-5 (data not shown).
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Serum MCP-1 and IL-8 Levels Were Elevated in
Lung Cancer Patients with Bone Metastases Compared
with the Localized Cancer
Both MCP-1 and IL-8 were reported to be produced by lung cancer
A549 cells [24,25]; however, there are few reports on the clinical roles
of both factors in lung cancer progression, although IL-8 was suggested
as one of the important angiogenic factors in non–small cell lung can-
cer [25–29]. Therefore, serum MCP-1 and IL-8 levels in lung cancer
patients and healthy age-matched donors were examined by ELISA. As
shown in Figure 3, MCP-1 levels were significantly elevated in patients
with localized lung cancer (mean ± SD was 92.28 ± 11.19 pg/ml)
compared with healthy donor (mean ± SD was 52.95 ± 14.3 pg/ml).
Importantly, MCP-1 levels were significantly increased in lung cancer
patients with bone metastases (mean ± SD was 118.71 ± 9.60 pg/ml)
compared with those in patients with localized cancer (P < .001,
t test). IL-8 levels, in a similar manner, were significantly elevated
in patients with localized lung cancer (mean ± SD was 206.33 ±
55.87 pg/ml) compared with those in healthy donors (mean ± SD was
Figure 1. Lung cancer cells produced high amounts of MCP-1 and IL-8. The cytokines’ production in CM collected from lung cancer cells
was measured using a human cytokine antibody array. (A) Images of the array that were assayed with CM obtained from control media,
BEAS2B, H1299, and A549 cells. Details of the procedure are described in Materials andMethods. The signals of MCP-1, RANTES, ENA-78,
GRO, GROα, IL-8, VEGF, CXCL16, MMP-9, and TIMP-4 were labeled with rectangles. (B) Radiographs of the arrays were scanned to de-
termine the density of each cytokine. Data are presented as a mean value of fold increase relative to control media. The value for each scan
was adjusted based on the intensity of positive control spots on each membrane.
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79.25 ± 23.08 pg/ml). IL-8 levels were significantly increased in lung
cancer patients with bone metastases (mean ± SD was 392.29 ±
134.23 pg/ml) compared with those in patients with localized cancer
(P < .01, t test).
Neutralizing Antibodies against MCP-1 Inhibited the
Lung Cancer CM–Induced Osteoclast Formation
Next, to test the functional role of MCP-1 in lung cancer–induced
bone resorptive lesions in vitro, we determined lung cancer A549 CM–
induced osteoclast formation using mouse bone marrow–derived mono-
cytes (MBMCs) in the presence of neutralizing antibodies for MCP-1,
IL-8, RANKL, or combination of the two or three antibodies. A549
CM induced multinucleated osteoclast-like cell formation, and this in-
ductionwas significantly diminished by each individual antibody,whereas
the adding of three antibodies blocked more than 80% of osteoclast for-
mation (Figure 4, A and B). Neutralizing antibody against MCP-1 effi-
ciently blocked the osteoclast fusion. A549 CM–induced osteoclast
formation and bone resorption fromMBMC were dose-dependently in-
hibited by adding anti–MCP-1–neutralizing antibodies and were further
synergistically inhibited with the addition of anti–IL-8 and anti-RANKL
Figure 3. Box plot of serum MCP-1 and IL-8 levels in lung cancer patients and healthy donors. Serum levels of MCP-1 and IL-8 in lung
cancer patients with localized cancer (n= 18) and bone metastases (n = 7) and in healthy donors (n= 20) were measured by ELISA. The
minimum detectable level of MCP-1 is typically less than 5.0 pg/ml. Statistical significance was determined using Student’s t test. *P <
.001 compared with healthy donors. †P < .001 compared with the patients with localized cancer. ‡P < .01 compared with the patients
with localized cancer. Horizontal lines in the box represent the first, second (the median), and third quartiles; whiskers (vertical lines)
represent extension of data up and down.
Figure 2. Confirmation of cytokine array data by ELISA. ELISA assays were performed with the CM used for the cytokine antibody array.
Data are presented as mean ± SD from triplicates. *P < .001 compared with the control media. †P < .001 compared with BEAS2B.
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(data not shown). These results indicate that MCP-1 may play a key role
in tumor-induced osteoclast formation in vitro.
Knockdown of MCP-1 in A549 Cells Diminished
the Tumor Growth in Bone
To determine the role of MCP-1 in lung cancer–induced bone re-
sorptive lesions in vivo, the A549 cells were stably transfected with
shRNA targeting MCP-1 or a scrambled shRNA. Production of
MCP-1 in the knockdown cells was examined by ELISA. We con-
firmed 88% and 56% knockdown of the MCP-1 production in the
selected clone 4 and clone 7, respectively (Figure 5A). We found that
IL-8 levels were not altered in these selected clones. Using the selected
A549 clones, we determined the cell proliferation in vitro by an MTS
assay to rule out a possibility of off-target effects of stable siRNA ex-
pression. As shown in Figure 5B, we found minimal inhibition of
cell proliferation in the selected clone 4 only at 48 hours but not at
72 and 96 hours. We did not observe significant inhibition in clone 7
at any time point. Then the two clones that stably transfected with
shRNA targeting MCP-1 or the control cells that stably transfected
with scrambled shRNA were injected into the tibiae of SCID mice
(n = 10 per group). The tumors were allowed to grow for 4 weeks.
TheMCP-1 knockdown in A549 cells significantly diminish the tumor
volume compared with the control cells determined by bone histomor-
phormetry (Figure 5C ). Furthermore, TRAP staining at the tumor-
bone interface demonstrated that the tumor-induced osteoclast activity
was significantly reduced by MCP-1 knockdown A549 cells compared
Figure 4. Neutralizing antibodies for MCP-1 inhibited lung cancer A549 CM–induced osteoclast formation. Nonadherent MBMC was
cultured at 1 × 105 per well in 96-well plates for 7 to 10 days. The cells were incubated with recombinant mouse M-CSF (10 ng/ml)
and/or RANKL (50 ng/ml) and 10% CM collected from the BEAS2B, H1299, or A549 cells in the presence of various doses of neutralizing
antibodies against MCP-1 (1 μg/ml), IL-8 (200 ng/ml), and RANKL (1 μg/ml). (A) Representative micrographs of MBMC cell cultures
stained for TRAP. (B) The number of osteoclast-like multinucleated cells per well was quantified. Samples were evaluated in quadrupli-
cate. Results are reported as mean (±SD). Data were analyzed using one-way analysis of variance. *P < .001 compared with BEAS2B
CM–treated group. **P < .01 compared with A549 CM–treated group. †P < .001 compared with A549 CM–treated group.
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with the control cells (Figure 5C). The proportion of theMCP-1 knock-
down for a given cell line was correlated with the proportion of ablation
of the bone lesions and osteoclast activity at the tumor-bone interface.
These results demonstrate a direct effect of MCP-1 produced by lung
cancer cells on osteoclast activity in vivo.
Discussion
Chemokines comprise a family of structurally related small proteins
that are involved in the inflammatory responses through their ability to
recruit leukocytes. In cancer development, specifically in cancer bone
metastases, the expression of certain chemokines, such as SDF-1/
CXCL12, fractalkine/CX3CL1, IL8/CXCL8, and MCP-1/CCL2,
and their receptors, CXCR4, CXCR1, CXCR2, and CCR2, respec-
tively, has been identified in cancer cells and/or other cell types in
the tumor growth microenvironment [15,21,30–37]. These cancers in-
clude various types of cancer, such as prostate and breast cancers, which
are the tumors that preferentiallymetastasize to bone [15,30,34,35,37,38].
Although very frequent, bone lesions due to lung cancer have been
Figure 5. Knockdown MCP-1 in A549 cells diminished the tumor growth in bone. (A) ELISA was performed in the CM from the selected
A549 cells that were stably transfected with shRNA targeting of either MCP-1 or a scrambled control. *P < .001 compared with wild
type (WT) or control shRNA cells. (B) MCP-1 knockdown in A549 cells minimally decreased the tumor cell proliferation as determined by
MTS assay. *P < .01, significant difference from the control cells by t test. (C) Single-cell suspension of the selected A549 cells was
injected into the right tibia of SCID mice. The tumor cells were allowed to grow for 4 weeks, at which time the mice were killed. Evidence
of tumor-induced bone osteolysis was evaluated by x-ray, H&E staining, and TRAP staining. On the x-ray film, arrows point to the tumor-
induced osteolysis. On TRAP staining, T represents tumor cells, B represents bone, OC represents osteoclast, and arrows point to the
increased osteoclast activities. Osteoclast number per millimeter bone surface is determined by bone histomorphometry. Tumor volume
versus non–bone soft tissue volume was quantified by bone histomorphometry. Results are reported as mean ± SD. *P < .001 compared
with the control cells.
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neglected research-wise compared with the analog condition caused by
other neoplasms. In this report, using a human cytokine antibody ar-
ray, we found that both lung cancer cell lines A549 and H1229 pro-
duced significantly higher amounts of MCP-1, IL-8, RANTES, ENA
78, GROα, VEGF, CXCL16, and MMP-9 compared with BEAS2B
cells. These results are similar to that we have reported in prostate
cancer [19]. Although the roles of RANTES, ENA 78, GROα, VEGF,
CXCL16, and MMP-9 in lung cancer development are currently on-
going studies, our results from this report suggest that MCP-1 medi-
ates lung cancer–induced osteoclast activity both in vitro and in vivo.
From clinical serum specimens, we further observed that MCP-1
levels, as well as IL-8 levels, were elevated in patients with localized
lung cancer compared with those in healthy donors. Importantly, we
found that serumMCP-1 and IL-8 levels were increased in lung cancer
patients with bone metastases compared with those in patients with
localized cancer. These results suggest that MCP-1 and IL-8 could
be used as biomarkers for the tumor progression, specifically for bone
metastases. Consistent with this report, it has been reported that vari-
ous cancer cells that preferentially home to bone, including prostate
cancer, breast cancer, and myeloma cells, express MCP-1 and its recep-
tor CCR2 [9,13–15]. In patients with breast and ovarian cancers, it
has been also reported that increased serum MCP-1 levels are associ-
ated with the tumor stages [16,17,39].
Osteoclast activities are important to the development of bone
metastases in solid cancer types. Soluble factors, for example, IL-8,
were recently reported to promote tumor-induced osteolysis in breast
cancer bone metastatic animal model [40]. In the current report, we
extended these findings to lung cancer. We showed that A549 CM
induced osteoclast formation that was inhibited by neutralizing anti-
bodies against MCP-1. This effect was additive to adding neutralizing
antibodies against IL-8 and RANKL, two of the key regulators in osteo-
clastogenesis. We postulate that a few cytokines, in a manner of net-
work, may play key roles in the interaction between the tumor cells
and the cells in the bone microenvironment.
To determine the effects of deleting MCP-1 expression on lung
cancer A549 cells–induced bone resorptive lesions in animals, we used
an intratibial injection murine model. The selected MCP-1 knock-
down A549 cells were injected into SCID mice. We showed that
MCP-1 knockdown A549 cells significantly diminished the tumor
growth in bone determined by histopathology and bone histomor-
phometry. We also observed reduction in numbers of tumor-induced
osteoclasts at the tumor and bone interface, which is consistent with
the observed inhibition of osteoclast formation in vitro. Furthermore,
our in vivo data have demonstrated the intrinsic nature of A549 cells to
be osteoclastic. Thus, a decrease in A549 growth in bone is associated
with a reduction in osteoclast activity. Therefore, we conclude that
MCP-1, produced by human lung cancer cells, promotes the tumor-
induced resorptive lesions in vivo. In support of our findings, it was
very recently reported that systemic delivery of neutralizing antibodies
against MCP-1 induced prostate cancer tumor regression in murine
models [21].
Critically, we observed that the proportion of the MCP-1 knock-
down in A549 cells was correlated with the proportion of ablation of
the bone lesions. These results suggest that MCP-1 is indeed one of
the key mediators in the lung cancer cell–induced bone lesions. To
consider off-target effects of stable siRNA expression, we performed
an in vitro cell proliferation assay to test whether MCP-1 knockdown
affects tumor cell proliferation. Interestingly, we observed minimal,
if there is any, inhibition of A549 cell proliferation. These results
excluded the possibility that MCP-1 knockdown in A549 cells that
diminished the tumor growth in bone was solely due to the decreased
cell proliferation. Taken together, the most interesting significance of
the current study is the increased MCP-1 in the circulation in lung
cancer patients with bone metastases compared with the localized
cancer. Future studies should address the origin of MCP-1 and ad-
dress whether it could be used as a prognostic biomarker for cancer
development. Nevertheless, the results from this study warrant future
clinical exploration of targeting MCP-1 that could eventually be used
in a variety of cancer types.
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